Can I Take St. John's Wort with Fosamax (Alendronate)?

The Short Answer: Why This Combination Deserves a Closer Look

The headline answer is reassuring but incomplete. Alendronate is not metabolized by the liver's cytochrome P450 enzyme system, so St. John's Wort's well-documented CYP3A4 induction activity does not create the classic pharmacokinetic drug interaction you might expect [1]. You will not, for example, see alendronate cleared faster from your bloodstream because you are also taking St. John's Wort.

"no direct pharmacokinetic interaction" is not the same as "safe to combine freely." Two separate concerns remain.

First, St. John's Wort appears to have weak estrogen-receptor-modulating properties, and there is observational evidence that it may reduce bone mineral density (BMD) independently of alendronate [2]. If you are taking alendronate specifically to build or preserve bone, adding a supplement that may work against that goal is counterproductive.

Second, timing matters for alendronate in ways that are stricter than almost any other oral drug. Getting the dosing window right is non-negotiable.

Both concerns are explained in detail below, with the evidence graded honestly.

How Alendronate Works in Your Body (and Why Metabolism Doesn't Apply Here)

Alendronate's absorption pathway

Alendronate is a bisphosphonate. After you swallow it, it is absorbed in the upper gastrointestinal tract and then deposited directly into bone, where it inhibits osteoclast-mediated bone resorption [3]. Roughly 50% of absorbed alendronate is taken up by bone tissue; the remainder is excreted unchanged in urine within 72 hours [4]. No hepatic metabolism. No CYP enzymes involved. This is why the St. John's Wort / CYP3A4 induction story simply does not apply.

Why dosing timing still matters

What does matter enormously is the absorption window. Oral bioavailability of alendronate is already low, averaging only 0.6% under ideal fasting conditions [4]. Coffee, orange juice, calcium supplements, antacids, or any food taken within 30 minutes of alendronate can reduce that absorption by up to 60% [5]. The FDA-approved prescribing information for alendronate specifies that the tablet must be taken:

• First thing in the morning with 6 to 8 ounces of plain water
• At least 30 minutes before the first food, beverage, or other medication of the day
• While remaining upright (sitting or standing) for at least 30 minutes to reduce esophageal irritation risk [5]

St. John's Wort supplements, like calcium, magnesium, and iron, should be taken at least two hours after alendronate. Not because of a metabolic interaction, but because any supplement taken in proximity risks physically impairing absorption.

St. John's Wort and Bone Health: The Indirect Risk Women Need to Know

What the research actually shows

This is the part most interaction-checkers miss. A 2011 cross-sectional analysis found that postmenopausal women using St. John's Wort had lower lumbar spine BMD compared with non-users after adjusting for age, body mass index, and physical activity [2]. The mechanisms proposed include:

• Hyperforin (one of the active constituents) may bind to steroid hormone receptors and partially antagonize estrogen signaling in bone
• St. John's Wort activates the pregnane X receptor (PXR), which increases the catabolism of vitamin D, and vitamin D deficiency is itself a known driver of bone loss [6]

The PXR-vitamin D link is particularly relevant for women on alendronate. Alendronate's efficacy depends on adequate vitamin D and calcium intake [7]. ACOG's 2021 Practice Bulletin on osteoporosis states that bisphosphonate therapy should be accompanied by calcium and vitamin D supplementation unless serum levels are already replete [7]. If St. John's Wort is simultaneously accelerating vitamin D catabolism, the foundation under your alendronate therapy may be quietly eroding.

How strong is this evidence?

Honest answer: not strong enough to be definitive. The 2011 study was cross-sectional, meaning it cannot prove causation. Randomized controlled trial data on St. John's Wort and BMD in women is sparse, and women were underrepresented in most St. John's Wort pharmacology studies. The PXR-vitamin D mechanism is well-established in cell and animal models [6], but human BMD data specific to women on bisphosphonates who also take St. John's Wort does not yet exist in sufficient volume.

This is the WomanRx Evidence Grade Framework applied to this combination:

| Domain | Finding | Evidence Quality | |---|---|---| | Direct PK interaction (CYP3A4) | None expected | Strong (mechanism rules it out) | | Absorption interference (timing) | Possible if taken together | Moderate (class-level data) | | BMD reduction by SJW | Possible indirect harm | Low-moderate (1 observational study) | | Vitamin D catabolism via PXR | Biologically plausible | Moderate (mechanistic + animal data) |

Given the observational evidence and plausible mechanism, it would be reasonable to check your vitamin D level (25-OH vitamin D) before starting or continuing St. John's Wort alongside alendronate. Target 25-OH vitamin D above 30 ng/mL for women on bisphosphonate therapy [7].

St. John's Wort and CYP3A4: Why This Matters for Your Other Medications

Even though CYP3A4 induction is not the concern with alendronate specifically, you may be taking other medications that are CYP3A4 substrates. This is especially relevant for women in perimenopause or postmenopause, who are often managing multiple conditions simultaneously.

St. John's Wort is one of the most potent known inducers of CYP3A4 and P-glycoprotein [1]. Drugs whose plasma levels can be significantly reduced by St. John's Wort include:

• Oral contraceptives and hormonal contraceptives (reducing efficacy, with pregnancy risk if you are using OCPs for perimenopausal cycle control)
• Hormone therapy preparations containing estradiol or progestin
• Cyclosporine, warfarin, digoxin, antiretrovirals, and several antidepressants [1]

If you are a perimenopausal woman taking both hormone therapy and alendronate, adding St. John's Wort may reduce hormone therapy plasma levels and blunt symptom control without you knowing why. The FDA issued a public health advisory specifically warning about St. John's Wort interactions with multiple drug classes [8]. Tell your clinician about all supplements you take, including St. John's Wort, before any medication regimen change.

Life-Stage Considerations: Who Is Most Affected?

Reproductive years (ages 18-40)

Alendronate is rarely prescribed during the reproductive years except for glucocorticoid-induced osteoporosis or rare conditions such as osteogenesis imperfecta. If you are of reproductive age and taking alendronate, contraception is mandatory (see the pregnancy section below). St. John's Wort may reduce oral contraceptive efficacy, which creates a direct conflict if you are relying on the pill for contraception while on alendronate [1].

Perimenopause (typically ages 45-55)

This is when bone loss accelerates most sharply. Women can lose up to 20% of bone density in the five to seven years around menopause [9]. Many perimenopausal women turn to St. John's Wort for mood and sleep support before seeking a prescription. If you are in this life stage, the risk-benefit calculation is worth an explicit conversation with your clinician: St. John's Wort may offer mild benefit for low-to-moderate depression (evidence from the Cochrane review of 35 trials showed superiority over placebo for mild-to-moderate depression) [10], but layering it over a treatment meant to protect bone requires attention to the vitamin D pathway.

Postmenopause

Approximately 1 in 2 women over age 50 will have an osteoporosis-related fracture in their lifetime [7]. Alendronate reduces vertebral fracture risk by approximately 47% and hip fracture risk by approximately 51% in postmenopausal women with osteoporosis, based on the Fracture Intervention Trial (FIT) [11]. Protecting that efficacy is the priority. Anything that erodes vitamin D status or interferes with absorption timing undermines a therapy with this level of established benefit.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

Alendronate in pregnancy

Alendronate is FDA Pregnancy Category C, meaning animal reproduction studies have shown adverse effects and there are no adequate, well-controlled studies in pregnant women [5]. Bisphosphonates accumulate in bone and can persist in the skeleton for years. Case reports suggest fetal skeletal abnormalities after maternal bisphosphonate use, though the absolute risk in humans is not well quantified [12].

The clinical recommendation is clear: alendronate should be avoided in pregnancy. Women of reproductive age who are prescribed alendronate should use reliable contraception throughout treatment and for at least six months after stopping, given the prolonged skeletal retention of the drug [5].

Alendronate in lactation

Alendronate is not known to transfer substantially into breast milk due to its rapid bone uptake and low plasma levels, but no adequate lactation pharmacokinetic studies exist in humans [5]. Given the theoretical risk and the availability of alternative bone-protective strategies during lactation, most clinicians advise against use. Discuss the timing of any planned pregnancy or lactation period with your prescriber well in advance.

St. John's Wort in pregnancy and lactation

St. John's Wort is contraindicated in pregnancy. A systematic review published in BJOG identified evidence of uterotonic activity in cell models and insufficient human safety data to support use [13]. In lactation, hyperforin and hypericin transfer into breast milk; case reports describe infant colic, drowsiness, and lethargy in breastfed infants whose mothers used St. John's Wort [13]. Do not use St. John's Wort if you are pregnant, trying to conceive, or breastfeeding.

Contraception requirement summary

If you are of reproductive age and taking alendronate:

• Use a reliable, non-hormonal contraceptive method if you are also taking St. John's Wort, given the risk of reduced oral contraceptive efficacy [1]
• Barrier methods (copper IUD, condoms) are not affected by St. John's Wort
• Inform your prescriber if you are planning a pregnancy so alendronate can be tapered and a drug holiday planned well in advance

Female-Relevant Conditions This Combination Touches

PCOS and bone health

Women with PCOS have a complex metabolic profile. Some research suggests PCOS is associated with higher BMD during the reproductive years due to elevated androgens and estrogen, but this does not eliminate long-term fracture risk, particularly if anovulatory cycles result in prolonged estrogen deficiency [14]. If you have PCOS and your clinician has prescribed alendronate (an unusual but not unheard-of scenario in the context of glucocorticoid treatment for adrenal hyperactivity), the St. John's Wort interaction considerations above apply equally.

Thyroid conditions and bone

Women with a history of hyperthyroidism or those on suppressive thyroid hormone therapy for thyroid cancer already face elevated bone turnover. TSH suppression below 0.1 mIU/L is associated with a significant reduction in BMD [15]. St. John's Wort also induces the metabolism of levothyroxine via CYP3A4 and glucuronidation pathways, which can reduce thyroid hormone levels and prompt your clinician to increase your dose, creating further bone-suppressive risk [1]. This is a layered interaction worth flagging explicitly.

Postpartum bone loss

Pregnancy-associated osteoporosis, a rare but real condition, is sometimes treated with bisphosphonates. If you have experienced a fragility fracture in the postpartum period, St. John's Wort use during this time is contraindicated because of lactation transfer concerns and the vitamin D catabolism risk at a time when bone is already under stress [13].

Who Should and Should Not Combine These Two

Women for whom this combination is lower risk (with precautions)

• Postmenopausal women taking St. John's Wort only for mild-to-moderate depressive symptoms, provided vitamin D is checked and maintained above 30 ng/mL, timing is separated by at least two hours, and no interacting co-medications are present
• Women not on hormone therapy, oral contraceptives, or other CYP3A4-sensitive drugs

Women who should avoid this combination or use extreme caution

• Any woman of reproductive age relying on hormonal contraception for pregnancy prevention while on alendronate
• Women on hormone therapy for menopausal symptoms (St. John's Wort may reduce estrogen/progestin levels and worsen symptom control)
• Women with thyroid disease on levothyroxine (triple interaction risk: bone, thyroid, drug metabolism)
• Women with known vitamin D deficiency or malabsorption syndromes
• Pregnant women or those planning pregnancy within the next 12 months (both agents are contraindicated or strongly cautioned)
• Women on warfarin, cyclosporine, antiretrovirals, or antiepileptics alongside alendronate (St. John's Wort's CYP3A4 effects become clinically important for these co-medications) [1]

Practical Guidance: If You Are Already Taking Both

If you are currently taking St. John's Wort and alendronate together, here is what to do, not in order of importance but in order of urgency:

Step 1. Do not stop alendronate abruptly without speaking to your prescriber. Stopping a bisphosphonate incorrectly can trigger a rebound in bone resorption markers.

Step 2. Check your 25-OH vitamin D level at your next blood draw if you have not done so in the past six months. Ask for a result above 30 ng/mL; below 20 ng/mL is deficient and may require prescription-dose supplementation alongside your alendronate [7].

Step 3. Confirm your dosing timing. Alendronate must be taken first thing in the morning with plain water, 30 minutes or more before any other supplement, food, or drink [5]. St. John's Wort should be taken at a separate time (mid-morning or with lunch is practical for most women).

Step 4. Tell your prescriber and pharmacist that you are combining these. Even though the direct pharmacokinetic interaction is unlikely, your full medication list needs review for CYP3A4-sensitive co-medications.

Step 5. If you are taking St. John's Wort for mood, anxiety, or sleep, ask your prescriber whether an evidence-based alternative is appropriate. Cognitive behavioral therapy for insomnia (CBT-I), low-dose SSRIs, or in the context of perimenopause, hormone therapy, may offer better-studied options without the PXR-vitamin D concern.

Monitoring Parameters When Taking Alendronate

Whether or not you use St. John's Wort, these are the standard monitoring checkpoints for women on alendronate:

• Baseline DEXA scan before starting, repeated at 1 to 2 years to assess treatment response [7]
• Serum 25-OH vitamin D before starting and annually; target above 30 ng/mL
• Serum calcium before starting; hypocalcemia must be corrected before initiating alendronate [5]
• Renal function (eGFR) before starting; alendronate is not recommended if eGFR is below 35 mL/min/1.73 m² [5]
• Esophageal symptom review at each visit; any new dysphagia or chest pain warrants immediate evaluation
• Drug holiday reassessment after 3 to 5 years of alendronate use; ACOG recommends discussing a drug holiday for lower-risk women after this period [7]